Long-term survival of cancer patients compared to heart failure and stroke: A systematic review

Abstract

BackgroundCancer, heart failure and stroke are among the most common causes of death worldwide. Investigation of the prognostic impact of each disease is important, especially for a better understanding of competing risks. Aim of this study is to provide an overview of long term survival of cancer, heart failure and stroke patients based on the results of large population- and hospital-based studies.MethodsRecords for our study were identified by searches of Medline via Pubmed. We focused on observed and relative age- and sex-adjusted 5-year survival rates for cancer in general and for the four most common malignancies in developed countries, i.e. lung, breast, prostate and colorectal cancer, as well as for heart failure and stroke.ResultsTwenty studies were identified and included for analysis. Five-year observed survival was about 43% for all cancer entities, 40-68% for stroke and 26-52% for heart failure. Five-year age and sex adjusted relative survival was 50-57% for all cancer entities, about 50% for stroke and about 62% for heart failure. In regard to the four most common malignancies in developed countries 5-year relative survival was 12-18% for lung cancer, 73-89% for breast cancer, 50-99% for prostate cancer and about 43-63% for colorectal cancer. Trend analysis revealed a survival improvement over the last decades.ConclusionsThe results indicate that long term survival and prognosis of cancer is not necessarily worse than that of heart failure and stroke. However, a comparison of the prognostic impact of the different diseases is limited, corroborating the necessity for further systematic investigation of competing risks.

Dosimetric Evaluation of 3-D Conformal and Intensity-modulated Radiotherapy for Breast Cancer after Conservative Surgery

“…A higher CI value indicates higher dose conformity to the target (Askoxylakis et al, 2010). The monitor unit counts (MU) required for treatment were recorded and compared between the techniques, between 564/fraction (fr) and 1054/fraction with IMRT, and between 328/(fr) and 517/(fr) en 3DCRT.…”

“…The disease is diagnosed in about 1.2 million patients and accounts for about 500,000 deaths yearly worldwide (Askoxylakis et al, 2010). The development of diagnostic strategies has led through the years to an earlier diagnosis of breast cancer, which resulted in the evolution from entirely surgical treatment into more conservative approaches, replacing mastectomy by breast-conserving surgery followed by radiation therapy in early-stage disease (Volker et al, 2011).…”

Myocardial cell sheet therapy and cardiac function

“…Survival rates and prognosis of patients with HF are as low as for cancer (3). In addition, HF patients who are resistant to conventional medical, surgical, and device therapy (cardiac resynchronization therapy) require a left ventricular assist device and/or cardiac transplantation (30).…”

Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada

“…Risks of death from hormonal therapy-related aes were obtained from various studies. The baseline mortality from stroke (13%) and any cardiac event (9%) were obtained from a systematic review that included twenty studies of long-term cancer survivors 18,19 . The base-case mortality from thromboembolic events (20%) was obtained from Canadian patients with solid tumours and acute venous thromboembolism participating in an open-label randomized controlled trial 16,17 .…”